WO2016097314A1 - Formes amorphes et cristallines d'idélalisib et procédé pour les produire - Google Patents

Formes amorphes et cristallines d'idélalisib et procédé pour les produire Download PDF

Info

Publication number
WO2016097314A1
WO2016097314A1 PCT/EP2015/080537 EP2015080537W WO2016097314A1 WO 2016097314 A1 WO2016097314 A1 WO 2016097314A1 EP 2015080537 W EP2015080537 W EP 2015080537W WO 2016097314 A1 WO2016097314 A1 WO 2016097314A1
Authority
WO
WIPO (PCT)
Prior art keywords
idelalisib
solvate
solvent
amorphous
crystalline
Prior art date
Application number
PCT/EP2015/080537
Other languages
English (en)
Inventor
Frank Richter
Verena Adamer
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15151854.5A external-priority patent/EP3048104A1/fr
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of WO2016097314A1 publication Critical patent/WO2016097314A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Definitions

  • the present invention concerns amorphous idelalisib, crystalline solvates of idelalisib and a process for the preparation of amorphous idelalisib using the crystalline solvates of idelalisib.
  • Bioavailability refers to the extent and rate at which the active moiety (drug or metabolite) enters systemic circulation, thereby accessing the site of action.
  • One important factor influencing the bioavailability of a medicament is the solubility of an API, in particular in those cases where the API has a low solubility and a high permeability.
  • an at least partial change of the degree of structural order of a pressure-sensitive solid form of the active pharmaceutical ingredient during the production of a compressed solid dosage form can also have negative implications for the relevant properties of the active pharmaceutical ingredient, such as compactability or compatibility with other excipients, thus impeding the process for the preparation of the compressed solid dosage form.
  • the use of pure solid forms of an API in pharmaceutical compositions is generally preferred over the use of solid form mixtures.
  • Idelalisib is a compound of the general formula (1 )
  • Idelalisib is a drug used for the treatment of chronic lymphocytic leukaemia.
  • the substance acts as a phosphoinositide 3-kinase (PI3K) inhibitor. Specifically, it blocks P1 10 ⁇ , the delta isoform of PI3K.
  • PI3K phosphoinositide 3-kinase
  • WO 2005/1 13554 A2 is directed to the synthesis of idelalisib and to compounds structurally related to idelalisib.
  • the crude product is purified by column chromatography, dissolved in ethanol and concentrated in vacuo to obtain a mixed ethanol/water solvate of idelalisib.
  • WO 2013/134288 A1 describes seven polymorphic forms of idelalisib.
  • Forms I and I I are crystalline and anhydrous.
  • Forms I I I to VI I are solvates of /so-propyl alcohol (I PA), dimethylformamide (DMF), dimethylsulfoxide (DMSO), dichloromethane (DCM) and ethanol, respectively.
  • Forms I I I and VI I contain varying amounts of water. Additionally, it is known that Form I easily converts at least partially to Form I I under pressure conditions which are typical for tablet preparation.
  • Idelalisib is commercially available under the trade name Zydelig®. However, Zydelig® tablets contain a mixture of both Forms I and I I of idelalisib.
  • amorphous idelalisib especially by pure amorphous idelalisib.
  • pure and stable amorphous idelalisib can be produced using novel (crystalline) solvates of idelalisib as intermediates.
  • ferf-butanol, tetrahydrofuran (THF) and /V,/V-dimethylformamide (DMF) solvates of idelalisib are useful for the preparation of pure amorphous idelalisib on an industrial scale.
  • Amorphous idelalisib produced using these novel solvates according to the present invention is essentially free from any crystalline forms of idelalisib, such as for example idelalisib crystalline Form I .
  • amorphous idelalisib according to the present invention is stable under tableting conditions as well as under high temperature/high humidity conditions and has improved solubility compared to crystalline forms of idelalisib known in the prior art.
  • it has been surprisingly found that amorphous idelalisib prepared from these new solvates is essentially free from chemical impurities. Preparing an amorphous compound essentially free from chemical impurities is often a challenging task.
  • the amorphous idelalisib according to the present invention has a very low content of residual solvents. Preparing an amorphous compound having a very low content of residual solvents is often a challenging task.
  • the present invention relates to amorphous idelalisib having no noticeable peak in an X-ray powder diffractogram, when measured at a temperature of 25°C with Cu K-alpha radiation.
  • the present invention is directed to a process for the preparation of amorphous idelalisib comprising the steps of:
  • step (ii) dissolving the idelalisib solvate of step (i) in a solvent
  • the present invention is directed to a process for the preparation of amorphous idelalisib comprising the steps of:
  • the invention relates to crystalline idelalisib solvates selected from
  • A) ferf-butanol solvate characterized by data selected from one or more of the following: an X-ray powder diffraction pattern with characteristic peaks at 9.4 ⁇ 0.2, 18.9 ⁇ 0.2,
  • C) tetrahydrofuran solvate characterized by data selected from one or more of the following: an X-ray powder diffraction pattern with characteristic peaks at 17.5 ⁇ 0.2,
  • the present invention relates to a process for the preparation of idelalisib solvates of the present invention comprising the steps of (I) providing a solution of idelalisib in the corresponding solvent,
  • the invention concerns a process for the purification of crude idelalisib, comprising the steps of:
  • step (V) dissolving the crystalline solvate of idelalisib of step (IV) in a solvent
  • step (VI I) optionally drying the product obtained in step (VI), in order to yield amorphous, preferably pure amorphous idelalisib.
  • the invention relates to the use of a crystalline solvate of idelalisib for the preparation of amorphous idelalisib of the present invention.
  • the invention relates to amorphous idelalisib as described herein or to a crystalline solvate of idelalisib as described herein for use in the treatment of cancer.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising amorphous idelalisib as described herein or a crystalline solvate of idelalisib as described herein, and one or more pharmaceutically acceptable excipients.
  • Fig. 1 shows an X-ray powder diffraction (XRPD) pattern of amorphous idelalisib prepared by precipitation from ferf-butanol solvate of idelalisib.
  • XRPD X-ray powder diffraction
  • Fig. 2 shows an X-ray powder diffraction (XRPD) pattern of amorphous idelalisib after compression at 740 MPa for 4.5 days.
  • XRPD X-ray powder diffraction
  • Fig. 3 shows an X-ray powder diffraction (XRPD) pattern of the ferf-butanol solvate of idelalisib.
  • Fig. 4 shows a TG/DTA thermogram of the ferf-butanol solvate of idelalisib.
  • Fig. 5 shows an X-ray powder diffraction (XRPD) pattern of the tetrahydrofuran solvate of idelalisib.
  • Fig. 6 shows a TG/DTA thermogram of the tetrahydrofuran solvate of idelalisib.
  • Fig. 7 shows an X-ray powder diffraction (XRPD) pattern of the /V,/V-dimethylformamide solvate of idelalisib.
  • Fig. 8 shows a TG/DTA thermogram of the /V,/V-dimethylformamide solvate of idelalisib.
  • the invention is directed to amorphous idelalisib.
  • Amorphous idelalisib in the context of the present invention means isolated amorphous idelalisib which is essentially free from any crystalline form of idelalisib, such as Form I or Form I I . Further, preferably the amorphous idelalisib according to the present invention is essentially pure.
  • Essentially free in the context of the present invention means that no crystalline form, such as idelalisib crystalline Form I, can be detected by X-ray powder diffraction (XRPD) measurement, i.e. no peaks of a crystalline form of idelalisib can be observed in an XRPD measurement. Consequently, the amorphous idelalisib of the present invention is preferably phase pure. While a crystalline phase usually produces a distinctive XRPD pattern comprising sharp lines/peaks, amorphous materials produce a broad background signal. Hence, in an embodiment of the invention the amorphous idelalisib of the present invention preferably has a phase purity of 90% or more, more preferably of 95% or more, most preferably of 98% or more, as determined via XRPD.
  • XRPD X-ray powder diffraction
  • the invention is directed to amorphous form of idelalisib having no noticeable peak in a powder X-ray diffraction.
  • No noticeable peak in the context of the present invention means that the XRPD does not contain any peak that the person skilled in the art would recognize as being characteristic of a crystalline phase.
  • a peak characteristic of a crystalline phase is generally a sharp line.
  • a peak characteristic of a crystalline phase is regarded as a peak having a width at half of its height from the top to its root, i.e. where the peak starts from the baseline, of less than 1 ° 2-Theta.
  • a peak characteristic of a crystalline phase is regarded as a peak having a height to width ratio of 5 : 1 or more, wherein the width is measured at half of its height.
  • a peak characteristic of a crystalline phase cannot be confused by the person skilled in the art with a peak of the background, since a peak characteristic of a crystalline phase has an at least 5 times greater height than the height of the highest peaks of which the background line consists, preferably at least 10 times greater.
  • the amorphous idelalisib has an XRPD pattern substantially as shown in Fig. 1 .
  • “Substantially as shown in” in the context of the present invention means a pattern that is not necessarily identical to those depicted herein, but falls within the limits of experimental or statistical error or deviations when considered by the person skilled in the art.
  • “substantially as shown in” means the absence of peaks characteristic of a crystalline phase, while the background line or curve may have a different aspect.
  • the amorphous idelalisib having an XRPD pattern as shown in Fig. 2 has an XRPD pattern substantially as shown in Fig. 1 , since in Fig. 2 no noticeable peaks are present.
  • Amorphous idelalisib of the present invention is preferably pure in view of impurities derived from compounds other than idelalisib.
  • the terms "pure” or “substantially pure” in the context of the present invention refer to chemical purity of the amorphous idelalisib. Chemical purity of the amorphous idelalisib can for example be determined by H PLC analysis.
  • the amorphous idelalisib of the present invention has a chemical purity of 95 wt.% or more, preferably of 98 wt.% or more, more preferably of 99.5 wt.% or more, based on the total weight of the amorphous idelalisib.
  • amorphous idelalisib can be prepared according to the method of the present invention without using column chromatography.
  • the amorphous idelalisib thus preferably has a content of silica which is less than 0.5 wt.%, preferably is less than 0.3 wt.%, more preferably is less than 0.1 wt.%, further more preferably is less than 0.03 wt.%, most preferably is less than 0.01 wt%, based on the total weight of the amorphous idelalisib, which can be determined by sulphated ash analysis according to Ph. Eur. 6.0, 2.4.14.
  • amorphous idelalisib obtained in the present invention has a decreased level of residual solvents compared to the idelalisib solid forms known in the art.
  • the amount of residual solvent present in amorphous idelalisib can be determined by gas chromatography.
  • ISS internal standard solution
  • DMSO dimethyl sulfoxide
  • a standard stock solution for a mixture of residual solvents such as methanol, ethanol, acetone, ethyl acetate, THF, pyridine and DMF can be prepared by adding standards of the above solvents in DMSO to produce a solution containing 1 mg/ml of each methanol, ethanol, ferf-butanol, acetone and ethyl acetate, 0.07 mg/ml tetrahydrofurane, 0.02 mg/ml pyridine and 0.09 mg/ml DMF.
  • 5 ml of the stock solution can be transferred to a 20 ml headspace vial.
  • One ml ISS can be added, and diluted to 10 ml with DMSO.
  • the vial is to be sealed after the addition.
  • Amorphous idelalisib 200 mg is to be weighed accurately and can be added into a 20 ml headspace vial.
  • One ml ISS is to be added, then diluted to 10 ml and the vial is then to be sealed.
  • the spiked sample solution can be prepared by weighing 200 mg of amorphous idelalisib into six headspace vials and 1 ml_ ISS of is to be added to each vial. Five ml stock solution can be transferred into each vial and diluted with DMSO to 10ml. The vials are to be sealed.
  • Carrier Nitrogen constant flow mode, 4.5 mL/min
  • OMI organic volatile impurity
  • ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
  • ICH makes recommendations as to what amounts of residual solvents are considered safe in pharmaceuticals.
  • Solvents in Class 1 should not be employed in the manufacture of drug substances, excipients, and drug products because of their unacceptable toxicity or their deleterious environmental effect. However, if their use is unavoidable in order to produce a drug product with a significant therapeutic advance, then their levels should be restricted. Solvents in Class 1 comprise for example benzene, carbon tetrachloride, 1 ,2- dichloroethane, 1 , 1 -dichloroethene and 1 , 1 , 1 -trichloroethane. Solvents in Class 2 should be limited in pharmaceutical products because of their inherent toxicity. Permitted daily exposures (PDEs) are given to the nearest 0.1 mg/day, and concentrations are given to the nearest 10 ppm.
  • PDEs Permitted daily exposures
  • Solvents in Class 3 may be regarded as less toxic and of lower risk to human health.
  • Class 3 includes no solvent known as a human health hazard at levels normally accepted in pharmaceuticals. It is considered that amounts of these residual solvents of 50 mg per day or less (corresponding to 5,000 ppm) would be acceptable without justification.
  • Class 4 solvents may also be of interest to manufacturers of excipients, drug substances, or drug products. However, no adequate toxicological data on which to base a PDE were found.
  • ICH Class 4 solvents comprise isooctane, isopropyl ether, petroleum ether and trichloroacetic acid.
  • the present invention relates to amorphous idelalisib wherein at most 300 ppm of I CH Class 2 solvents are present.
  • at most 200 ppm such as at most 150 ppm, such as at most 100 ppm, such as at most 90 ppm, at most 80 ppm, at most 70 ppm, at most 60 ppm, at most 50 ppm, at most 40 ppm, at most 30 ppm, at most 20 ppm and most preferably at most 10 ppm residual ICH Class 2 solvents are present.
  • the present invention also relates to amorphous idelalisib which is substantially free of ICH Class 2 solvents, in particular essentially free from tetrahydrofuran and /V,/V-dimethylformamide.
  • the obtained amorphous idelalisib of the present invention has an overall organic volatile impurity content of up to 300 ppm, such as up to 100 ppm, for example 50 ppm, and being essentially free from ICH Class 2 solvents, such as tetrahydrofuran and /V,/V-dimethylformamide. It is a further advantage of the amorphous idelalisib of the present invention that it is stable at high temperatures and/or high relative humidity.
  • the amorphous idelalisib does not have any noticeable peak, especially any peak characteristic of a crystalline form of idelalisib, in a powder X-ray diffraction after 120 hours storage at 120°C.
  • the amorphous idelalisib has an XRPD pattern substantially as shown in Fig. 1 after 120 hours storage at 120°C.
  • the amorphous idelalisib does not have any noticeable peak, especially any peak characteristic of a crystalline form of idelalisib, in a powder X-ray diffraction after 120 hours storage at 40°C/75% relative humidity.
  • the amorphous idelalisib has an XRPD pattern substantially as shown in Fig. 1 after 120 hours storage at 40°C/75% relative humidity.
  • the amorphous idelalisib does not have any noticeable peak, especially any peak characteristic of a crystalline form of idelalisib, in a powder X-ray diffraction after 120 hours storage at 25°C/98% relative humidity.
  • the amorphous idelalisib has an XRPD pattern substantially as shown in Fig. 1 after 120 hours storage at 25°C/98% relative humidity.
  • the pure amorphous idelalisib of the present invention may be further characterized by phase stability under tableting conditions. While the anhydrous crystalline Form I converts at least partially to a crystalline Form I I under pressure as applied during tableting, leading to a mixture of Forms I and I I, such as in the commercially available product Zydelig®, the amorphous idelalisib of the present invention does preferably not show any substantial phase conversion under compression. Thus, in one embodiment of the invention the amorphous idelalisib has an XRPD pattern substantially as shown in Fig. 2 after compression at 740 MPa for 4.5 days.
  • an XRPD pattern of amorphous idelalisib prior to compression is substantially as shown in Fig. 1 while an XRPD pattern of amorphous idelalisib after compression is substantially as shown in Fig. 2.
  • the XRPD patterns illustrated in Fig. 1 and 2 are regarded as being identical within statistical error.
  • the invention further relates to a process for the formation of pure amorphous idelalisib as described above.
  • pure amorphous idelalisib can be prepared by using solvates of idelalisib, preferably by using the solvates of the present invention which are described below. After removing the solvent from the solvates of idelalisib, amorphous idelalisib with higher purity than the starting material can be obtained.
  • the process of the present invention to obtain 1 ) amorphous idelalisib and 2) with a purity which could not be obtained with the conventional processes described in the prior art.
  • the process for the preparation of amorphous idelalisib comprises the steps of:
  • step (ii) dissolving the solvate of idelalisib of step (i) in a solvent
  • Step (i) is not limited to specific solvates of idelalisib.
  • the solvates of idelalisib are solvates selected from ferf-butanol, tetrahydrofuran, N,N- dimethylformamide, ethanol, dimethylsulfoxide (DMSO), isopropyl alcohol and dichloromethane. More preferably, the solvates of idelalisib are solvates selected from ferf-butanol, tetrahydrofuran and /V,/V-dimethylformamide. Most preferably, the solvates of idelalisib are the new solvates of the present invention.
  • step (ii) of dissolving the solvate of idelalisib of step (i) in a solvent is carried out at a temperature in the range of 20 to 50°C, more preferably in the range of 30 to 45°C.
  • the concentration of the solvate of idelalisib in the solution obtained in step (ii) is in the range of 15 to 1000 mg/mL, more preferably in the range of 50 to 750 mg/mL. Most preferably, the solution of the solvate of idelalisib obtained in step (ii) is saturated.
  • removing the solvent in step (iii) is typically performed by one or more of precipitation and filtration, thermal desolvation, hot melt-extrusion, spray drying, or lyophilization.
  • removing the solvent in step (iii) is performed by one or more of precipitation and filtration, spray drying, or lyophilization.
  • removing the solvent in step (iii) is carried out by adding the solution of step (ii) into water and filtrating the precipitate.
  • the solvent in step (ii) is selected from ethanol, methanol, dioxane, tetrahydrofuran and /V,/V-dimethylformamide, as well as mixtures thereof. More preferably, the solvent in step (ii) is ethanol.
  • the ratio between the volume of the solution of step (ii) and the volume of water to which the solution of step (ii) is added in order to lead to amorphous idelalisib to precipitate is in the range of 1 : 1 to 1 :40, such as 1 :2, 1 :3, 1 :4, 1 :5, 1 :6, 1 :7, 1 :8, 1 :9, 1 : 10, 1 : 15, 1 :20, 1 :30 and 1 :35.
  • the filtration of the amorphous idelalisib is not limited to specific methods known in the art.
  • the filtration of the amorphous idelalisib may therefore be carried out for example by centrifuge filtration.
  • step (iii) may further optionally be dried, for example under reduced pressure, typically at room temperature, or heated up to a temperature between 25°C and 90°C.
  • removing the solvent in step (iii) is carried out by spray or freeze drying the solution of step (ii).
  • Solvents in pure form or mixtures used for spray drying are preferably selected from Biopharmaceutics Classification System (BCS) Class 3 solvent(s), further preferably with a low boiling point, most preferably acetone and dichloromethane.
  • Solvents used for lyophilization are typically selected from dioxane, dimethylsulfoxide (DMSO), tetrahydrofuran, acetic acid, acetone, ethanol, methanol and ferf-butanol.
  • the solvent in step (ii) when step (iii) comprises a freeze drying (lyophilization) step is selected from dioxane, tetrahydrofuran, ethanol and methanol, as well as mixtures thereof. More preferably, the solvent in step (ii) is selected from dioxane, tetrahydrofuran and mixtures thereof.
  • the amount of the solvent is not particularly restricted, preferably a 10 to 100-fold amount with respect to the substrate.
  • the time for lyophilization is not particularly restricted, preferably 1 to 240 hours, more preferably 2 to 120 hours.
  • the process for the preparation of amorphous idelalisib comprises the steps of:
  • step (iv) separating at least a part of the solid material obtained in step (iii), and
  • the drying in step (ii) or (v) in two previous embodiments is performed at a temperature in the range from 20 to 80 °C.
  • slurrying in the context of the present invention encompasses any kind of movement of a solid material suspended in a solvent caused by, but not limited to e.g.
  • the present invention refers to novel crystalline solvates of idelalisib.
  • solvate of idelalisib is preferably synonymous to crystalline solvate of idelalisib, i.e. the solvates of idelalisib of the present invention are preferably isolated in solid form.
  • the novel crystalline solvates can be used as intermediates in the preparation of pure amorphous idelalisib as described herein.
  • the present invention relates to a crystalline idelalisib solvate selected from a ferf-butanol solvate, a tetrahydrofuran solvate and a /V,/V-dimethylformamide solvate.
  • crystalline idelalisib ferf-butanol solvate of the present invention is characterized by data selected from one or more of the following: a) an X-ray powder diffraction pattern with characteristic peaks at 9.4 ⁇ 0.2, 18.9 ⁇ 0.2, 22.8 ⁇ 0.2° 2-Theta when measured at a temperature of 25°C with Cu K-alpha radiation; b) an X-ray powder diffraction pattern substantially as depicted in Fig. 3; and by a combination of these data.
  • crystalline idelalisib ferf-butanol solvate is preferably characterized by a thermogravimetric/differential thermal analysis (TG/DTA) thermogram substantially similar to the one set forth in Fig. 4, when measured at a rate of 10°C/min from 30°C to 300°C.
  • TG/DTA thermogravimetric/differential thermal analysis
  • crystalline idelalisib tetrahydrofuran solvate is characterized by data selected from one or more of the following: a) an X-ray powder diffraction pattern with characteristic peaks at 17.5 ⁇ 0.2, 19.4 ⁇ 0.2, 21 .5 ⁇ 0.2° 2-Theta when measured at a temperature of 25°C with Cu K-alpha radiation; b) an X-ray powder diffraction pattern substantially as depicted in Fig. 5; and by a combination of these data.
  • crystalline idelalisib tetrahydrofuran solvate is preferably characterized by a thermogravimetric/differential thermal analysis (TG/DTA) thermogram substantially similar to the one set forth in Fig. 6, when measured at a rate of 10°C/min from 30°C to 300°C.
  • TG/DTA thermogravimetric/differential thermal analysis
  • crystalline idelalisib /V,/V-dimethylformamide solvate is characterized by data selected from one or more of the following: a) an X-ray powder diffraction pattern with characteristic peaks at 1 1 .8 ⁇ 0.2, 18.3 ⁇ 0.2, 20.1 ⁇ 0.2° 2-Theta when measured at a temperature of 25°C with Cu K-alpha radiation; b) an X-ray powder diffraction pattern substantially as depicted in Fig. 7; and by a combination of these data.
  • crystalline idelalisib /V,/V-dimethylformamide solvate is preferably characterized by a thermogravimetric/differential thermal analysis (TG/DTA) thermogram substantially similar to the one set forth in Fig. 8, when measured at a rate of 10°C/min from 30°C to 300°C.
  • TG/DTA thermogravimetric/differential thermal analysis
  • the crystalline solvates of idelalisib of the present invention may be characterized by the peaks listed in the following tables, showing the main 6 peaks (Table 1 ) and the main 10 peaks (Table 2) in an XRPD diffractogram.
  • the solvates of idelalisib of the present invention may be characterized by a stoichiometric composition of the solvates, i.e. the number of solvent molecules per idelalisib molecule.
  • the stoichiometry can be determined by DTA/TG and/or 1 H NMR.
  • the idelalisib ferf-butanol solvate preferably comprises ferf-butanol in the range of 0.2 mol to 1 .5 mol, more preferably in the range of 0.3 mol to 1 .3 mol, most preferably in the range of 0.4 mol to 1 .1 mol per mol idelalisib.
  • the idelalisib ferf-butanol solvate further comprises water.
  • the ferf-butanol solvate may contain water in the range of 0.5 to 5 mol per mol idelalisib, preferably in the range of 1 to 4 mol, more preferably in the range of 1 .5 to 3.5 mol water per mol idelalisib.
  • the idelalisib ferf-butanol solvate comprises ferf-butanol preferably in the range of 0.2 mol to 1 .5 mol, more preferably in the range of 0.3 mol to 1 .3 mol, most preferably in the range of 0.4 mol to 1 .1 mol per mol idelalisib and water preferably in the range of 0.5 to 5 mol per mol idelalisib, more preferably in the range of 1 to 4 mol, most preferably in the range of 1 .5 to 3.5 mol water per mol idelalisib.
  • the idelalisib tetrahydrofuran solvate preferably comprises tetrahydrofuran in the range of 0.1 mol to 1 .0 mol, more preferably in the range of 0.2 mol to 0.8 mol, most preferably in the range of 0.3 mol 0.7 mol per mol idelalisib.
  • the idelalisib /V,/V-dimethylformamide solvate preferably comprises /V,/V-dimethylformamide in the range of 0.5 mol to 1 .5 mol, more preferably in the range of 0.7 mol to 1 .3 mol, most preferably in the range of 0.8 mol to 1 .2 mol per mol idelalisib.
  • the idelalisib tetrahydrofuran and the /V,/V-dimethylformamide solvates may additionally comprise water in the range of 0 mol to 0.5 mol per mol idelalisib.
  • the solvates of the present invention can be prepared by a process comprising the steps of
  • the organic solvent in step (I) is preferably selected from ferf-butanol, ferf- butanol/water, tetrahydrofuran and /V,/V-dimethylformamide.
  • ferf-butanol/water is a mixture of ferf-butanol and water in a ratio in the range of 80:20 to 99.5:0.5, more preferably 85: 15 to 99: 1 , most preferably 90: 10 to 98:2 (v/v).
  • Dissolution of idelalisib in step (I) can be obtained at temperatures in the range of 4°C to 80°C depending on the solvent used, preferably in the range of 10 to 70 °C, more preferably in the range of 20 to 60°C, most preferably in the range of 30 to 50°C.
  • a crystalline form of idelalisib such as Form I, Form I I or a mixture of Forms I and I I, or amorphous idelalisib can be used as the idelalisib to be dissolved in step (I).
  • seed crystals may be added in step (I I).
  • the seed crystals are prepared by the same solvent used in step (I) of the process.
  • the seed crystals are prepared by the same process steps as the solvates of the present invention.
  • the seed crystals are typically added in an amount of 0.1 wt% to 10 wt%, preferably in an amount of 0.5 wt% to 7.0 wt%, most preferably 1 .0 wt.% 5.0 wt%, on the basis of the total amount of the starting material, i.e. the solution obtained in step (I).
  • step (I I I) the solution is transformed into a slurry by performing one or more of stirring the solution, or submitting the solution to one or more of temperature cycling, crash cooling, evaporation, or anti-solvent addition.
  • Stirring is performed at a temperature of 10°C to 100°C, preferably between 20°C and 50°C, most preferably at about room temperature, e.g. 22 to 25°C, typically for a period of time of 2 h to 21 days.
  • Temperature cycling is preferably performed at atmospheric pressure, preferably at 2 to 22°C or 20 to 80°C, but also other conditions may be used depending on the type of solvate to be produced. Temperature cycling is typically performed for a period of 16 to 24 hours by subjecting the solution or slurry to temperature cycles such as between 20°C and 80°C, wherein each cycle may have a length of between 0.5 and 8 hours, preferably about 2 hours.
  • a typical but not limiting temperature cycling protocol may be as follows: i) Heat from 20°C to 80°C (1 h) ii) Cool to 20°C (1 h).
  • Steps i) and ii) are typically repeated 5 to 10 times.
  • Crash cooling is typically performed by directly and rapidly cooling the solution from a temperature of between 25 and 50°C to a temperature of 2°C or below, such as a temperature between 0°C and -18°C, depending on the type of solvate, and keeping the solution at this temperature for example for 4 h to 24 h, such as for example 16 to 20 h.
  • Evaporation is typically performed at reduced pressure, but may also be achieved at atmospheric pressure.
  • the solvent used for anti-solvent addition may typically be selected from water, acetonitrile, a C1 -4 dialkylether, preferably methyltertbutylether (MTBE), or an alkane, preferably is selected from an alkane, more preferably a C5 alkane, a C6 alkane, a C7 alkane, a C8 alkane, or a mixture of two or more thereof, more preferably a C7 alkane, more preferably n-heptane.
  • the anti-solvent is water or n-heptane.
  • the addition of anti-solvent may be carried out at a temperature in the range of 0 to 25°C.
  • step (I I I) may be added in step (I I I) in case of formation of thick slurries to allow easier stirring of the resulting slurry.
  • step (I I I) comprises anti-solvent addition and evaporation.
  • the evaporation carried out after addition of anti-solvent leads to oily solutions or to clear solutions without precipitation.
  • the solutions may be sonicated before evaporation of the solvent.
  • isolation in step (IV) may be performed by using procedures known in the art, such as by filtration, centrifugation, or evaporation of solvent.
  • the isolated crystals may optionally be dried in step (V), e.g. under reduced pressure, typically at room temperature (25°C), or heated up to a temperature of between 25°C and 50°C or the crystals may directly be used in further processes, such as the preparation of amorphous idelalisib or isolated crystals may be used as seed crystals for the preparation of a solvate of idelalisib.
  • the invention further relates to the use of idelalisib solvates for the manufacture of amorphous idelalisib which can be obtained by the process of the invention in pure amorphous form.
  • amorphous idelalisib can be prepared by using the solvates of the present invention. After dissolving the solvates of the present invention in a solvent and removing the solvent, pure amorphous idelalisib can be obtained.
  • the present invention refers to a combination of the process for the preparation of the solvates of idelalisib and the process for the preparation of pure amorphous idelalisib, both as described herein.
  • crude idelalisib may be used as the starting material for the preparation of the solvates of idelalisib of the present invention, which may contain any chemical impurities, such as residual amounts of silica, or may contain residual amounts of crystal forms of idelalisib, such as the crystal form I of idelalisib, it is possible with the combination of both processes to obtain amorphous idelalisib with a higher purity than the starting material.
  • idelalisib such as crude idelalisib.
  • Crude idelalisib may be for example the mixed ethanol/water solvate of idelalisib obtained after column chromatography described in WO 2005/1 13554 A2.
  • “Crude” in the context of the present invention means having a chemical purity of less than 95 wt.%, based on the total weight of the idelalisib.
  • “crude” means having a phase purity of less than 90% in addition to the 95wt.% chemical impurity as described above.
  • Phase purity of less than 90% comprises an amorphous form and a crystalline form having a phase purity of less than 90%, respectively.
  • the present invention refers to a process for the purification of crude idelalisib, comprising the steps of:
  • step (V) dissolving the crystalline solvate of idelalisib of step (IV) in a solvent
  • step (VI I) optionally drying the product obtained in step (VI), in order to yield amorphous, preferably pure amorphous idelalisib.
  • Amorphous idelalisib with a higher purity, i.e. chemical and phase purity, than the crude idelalisib used as the starting material in step (I) is obtained in step (VI) or optionally in step (VI I).
  • the amorphous idelalisib obtained by the above process is substantially free from silica or from residual amounts of crystal forms of idelalisib such as crystal Form I of idelalisib, which, however, may be present in the crude idelalisib used as the starting material in step (I) of the process.
  • the preferred embodiments of the process are the same as described above for the process for the preparation of the solvates of idelalisib of the present invention and the process for the preparation of pure amorphous idelalisib and thus also refer to the combination of both processes.
  • cancer may be hematologic malignancy, preferably a B cell malignancy, preferably selected from chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), non-Hodgkin's lymphoma, indolent non- Hodgkin's lymphoma, diffuse large B Cell lymphoma (DLBCL), multiple myeloma (MM), marginal zone lymphoma (NHL), hairy cell leukemia, acute lymphocyte leukemia (ALL), acute myeloid leukemia (AML).
  • CLL chronic lymphocytic leukemia
  • SLL small lymphocytic lymphoma
  • MCL mantle cell lymphoma
  • NHL non-Hodgkin's lymphoma
  • indolent non- Hodgkin's lymphoma diffuse large B Cell lymphoma
  • DLBCL multiple myeloma
  • NHL marginal zone lympho
  • the present invention also refers to a pharmaceutical composition
  • a pharmaceutical composition comprising amorphous idelalisib as described herein or a crystalline solvate of idelalisib as described herein, as an active pharmaceutical ingredient.
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising amorphous idelalisib as an active pharmaceutical ingredient, and wherein at most 300 ppm of ICH Class 2 solvents are present.
  • at most 200 ppm such as at most 150 ppm, such as at most 100 ppm, such as at most 90 ppm, at most 80 ppm, at most 70 ppm, at most 60 ppm, at most 50 ppm, at most 40 ppm, at most 30 ppm, at most 20 ppm and most preferably at most 10 ppm residual ICH Class 2 solvents are present in the pharmaceutical composition of the invention.
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising amorphous idelalisib which is substantially free of ICH Class 2 solvents, in particular essentially free from tetrahydrofuran and /V,/V-dimethylformamide.
  • the pharmaceutical composition of the present invention contains as active pharmaceutical ingredient only amorphous idelalisib of the present invention.
  • the pharmaceutical composition of the present invention comprises idelalisib, wherein at least 90 wt.%, such as 95 wt.%, is amorphous idelalisib according to the present invention, based on the weight of idelalisib present in the pharmaceutical composition.
  • the pharmaceutical composition further comprises one or more
  • the one or more pharmaceutically acceptable excipients are selected from binders, fillers, lubricants, glidants,
  • the pharmaceutical composition is typically a solid oral dosage form. It may be administered to a subject by multiple administration routes, including but not limited to, oral ( non-limiting examples for suitable dosage forms include solid dosage forms, like tablets, powders, capsules, suppositories, sachets, troches and lozenges) , parenteral (( non-limiting examples, intravenous, subcutaneous, intramuscular), intranasal, buccal, topical, rectal, or transdermal administration routes. More details of oral solid dosage form compositions described in subsequent embodiments.
  • the pharmaceutical composition is a compressed solid oral dosage form.
  • the compressed dosage form is essentially free of crystalline idelalisib.
  • the present invention features a pharmaceutical composition comprising a stabilized pharmaceutical composition, wherein the composition comprises
  • a particular ratio of API idelalisib: matrix by weight is from 1 :0.25 to 1 : 10.
  • Suitable ratios are 1 :2, 1 :3 and 1 :4.
  • one or more surfactants will be present in the stabilized pharmaceutical composition in an amount of 0.1 to 50%, preferably :0.5% (eg, 1 to 2%) by weight of the solid dispersion.
  • the presence of a surfactants provides a further enhancement of the increase in therapeutic potential achieved with the present invention.
  • the organic matrix is selected from homopolymer of N-vinyl lactam, copolymer of N-vinyl lactam, cellulose ester, cellulose ether, polyalkylene oxide, polyacrylate, polymethacrylate, polyacrylamide, polyvinyl alcohol, vinyl acetate polymer, oligosaccharide, or polysaccharide.
  • Non-limiting examples of suitable hydrophilic polymers include homopolymer of N-vinyl pyrrolidone, copolymer of Nvinyl pyrrolidone, copolymer of N-vinyl pyrrolidone and vinyl acetate, copolymer of N-vinyl pyrrolidone and vinyl propionate, graft copolymer of polyethylene glycol/polyvinyl caprolactam/polyvinyl acetate (e.g., Soluplus ), polyvinylpyrrolidone, methylcellulose, ethylcellulose, hydroxyalkylcelluloses, hydroxypropylcellulose, hydroxyalkylalkylcellulose, hydroxypropylmethylcellulose, cellulose phthalate, cellulose succinate, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose succinate, hydroxypropylmethylcellulose acetate succinate, polyethylene oxide, polypropylene oxide, copolymer of
  • carbon black, cellulose, cellulose derivatives, polyols, sugars, sugar alcohols and other sugar derivatives e.g. , lactose, mannitol
  • starches pre-gelatinized starches, starch derivatives, modified, starches, dextrins, maltodextrins, polydextroses, dextroses, or their mixtures
  • Non-limiting examples of a preferred organic matrix for the invention include
  • Ethocel 7 EthoceM O
  • Ethocel14 Ethocel20
  • copovidone vinylpyrrolidone-vinyl acetate copolymer 60/40
  • polyvinyl acetate methacrylate/methacrylic acid copolymer
  • Non-limiting examples for a suitable inorganic matrix are Al 2 0 3 , MgO, Ti0 2 ZnO, calcium carbonate, calcium phosphate, calcium sulphate, Magnesium Alumino-metasilicates like Neusilin , dibasic calcium phosphates like Fujicalin, different grades of Melt-F or silicon dioxide, more preferably colloidal silicon dioxide or precipitated silicon dioxide characterized by high surface area due to open pores.
  • Suitable carriers are for example, Aerosil® 90, 130, 150, 200 or 380 or Aerosil® OX 50, EG 50 or TT 600
  • Syloid series such as Syloid 244 or Syloid AL-1 (Grace Davison, USA)
  • HDK pyrogenic silica series such as H DK N20 (Wacker Chemie AG, Germany) can be used.
  • Aerosil® 200 or Syloid 244 can be used, more preferably Syloid AL-1 can be used.
  • formulations are known in the art by melting (e.g. hot-melt extrusion, spray congrealing and melt granulation) or by typically comprising the steps of dissolving the drug and the matrix in a common solvent and evaporating the solvent( e.g. spray drying, solvent casting or freeze drining) or by using other technologies (e.g. milling, ball milling solvent controlled precipitation, pH controlled precipitation, supercritical fluid technology and cryogenic co milling).
  • melting e.g. hot-melt extrusion, spray congrealing and melt granulation
  • solvent e.g. spray drying, solvent casting or freeze drining
  • other technologies e.g. milling, ball milling solvent controlled precipitation, pH controlled precipitation, supercritical fluid technology and cryogenic co milling.
  • the formulation product or dose may comprise in addition one or more fillers, binders, disintegrants, plasticisers and/or lubricants.
  • the combined amount of excipients comprises, for example, 1 to 90% by weight of the formulation or dose.
  • the idelalisib will be present in an amount of 10 to 70%, and preferably from 15 to 50% (more preferably 20 to 30% or 25 to 35%) by weight of the solid dispersion.
  • one or more fillers will be present in an amount of 1 to 70% by weight of the formulation or dose.
  • one or more binders will be present in an amount of 2 to 40% by weight of the formulation or dose.
  • one or more disintegrants will be present in an amount of 1 to 25 20%, and especially 4 to 10% by weight of the formulation or dose. It will be appreciated that a particular excipient may act as both a binder and a filler, or as a binder, a filler and a disintegrant.
  • one or more lubricants will be present in an amount of 0.5 to 3%, and especially 1 to 2% by weight of the formulation or dose.
  • one or more plasticisers will be present in the solid dispersion in an amount of0.1 % to 50%, preferably: 0.5% (e.g. 1 to 2%) by weight of the solid dispersion.
  • suitable fillers include, for example, starches and modified starches, such as maize starch, potato starch, rice starch, wheat starch, pregelatinized starch, fully pregelatinized starch; cellulose derivatives (e.g.
  • microcrystalline cellulose, cellulose or silicified microcrystalline cellulose) sugars and sugar derivatives such as mannitol, erythritol; lactose, xylitol and lactitol such as lactosemonohydrate, lactose anhydrous, spray dried lactose or milled lactose; inorganic salts like calcium sulphate, calcium phosphate, calcium hydrogenphosphate, calcium carbonate
  • Non-limiting examples for suitable binders include, for example, lactose, starches, modified starches, sugars, gum acacia, gum tragacanth, guar gum, pectin, wax binders, microcrystalline cellulose, methylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, copolyvidone, gelatine, polyvinylpyrollidone (PVP) and sodium alginate
  • Non-limiting examples for suitable disintegrants include, for example, carmellose calcium, carboxymethylstarch sodium, croscarmellose sodium (cellulose
  • carboxymethylether sodium, salt, crosslinked), starch such as sodium starch glycolate or corn starch, crosslinked polyvinylpyrrolidone (crospovidone), and low-substituted hydroxypropylcellulose, microcrystalline cellulose, hydroxypropyl and methylcellulose
  • Non-limiting examples for suitable lubricants include, for example, stearic acid, glyceryl behenate, magnesium stearate, magnesium lauryl stearate, sodium stearyl fumarate, stearic acid, calcium stearate, zinc stearate, potassium benzoate, sodium benzoate, myristic acid, palmitic acid, mineral oil, hydrogenated castor oil, medium-chain triglycerides, poloxamer, polyethylene glycol and talc.
  • suitable lubricants include, for example, stearic acid, glyceryl behenate, magnesium stearate, magnesium lauryl stearate, sodium stearyl fumarate, stearic acid, calcium stearate, zinc stearate, potassium benzoate, sodium benzoate, myristic acid, palmitic acid, mineral oil, hydrogenated castor oil, medium-chain triglycerides, poloxamer, polyethylene glycol and talc.
  • Non-limiting examples of pharmaceutically acceptable surfactants that are suitable for the present invention are suitable for the present invention:
  • anionic surfactants such as sodium dodecyl sulphate (sodium lauryl sulphate); docusate sodium;
  • suitable cationic surfactants such as cetrimide, benzethonium chloride, cetylpyridinium chloride and lauric acid
  • suitable nonionic surfactants such as polyoxyethylene castor oil derivates, e.g.polyoxyethyleneglycerol triricinoleate or polyoxyl 35 castor oil (Cremophor EL; BASF Corp.) or polyoxyethyleneglycerol oxystearate such as polyethylenglycol 40 hydrogenated castor oil (Cremophor RH 40, also known as polyoxyl 40 hydrogenated castor oil or macrogolglycerol hydroxystearate) or
  • polyethylenglycol 60 hydrogenated castor oil (Cremophor RH 60); or a mono fatty acid ester of polyoxyethylene sorbitan, such as a mono fatty acid ester of polyoxyethylene (20) sorbitan, e.g. polyoxyethylene (20) sorbitan monooleate (Tween 80),
  • polyoxyethylene (20) sorbitan monostearate Tween 60
  • polyoxyethylene (20) sorbitan monopalmitate Tween 40
  • polyoxyethylene (20) sorbitan monolaurate Tween 20
  • a mixture of surfactants can be used in a solid composition of the present invention
  • Other suitable ionic or non-ionic surfactants may also be used.
  • Non-limiting examples of suitable plasticisers include: acetyltributyl citrate, acetyltriethyl citrate, benzyl benzoate, chlorbutanol, dextrin, dibutyl phthalate, diethyl phthalate, dimethyl phthalate, glycerine, glycerine monostearate, mannitol, mineral oil, lanolin alcohols, palmitic acid, polyethylene glycol, polyvinyl acetate phthalate, propylene glycol, 2-pyrrolidone, sorbitol, stearic acid, triacetin, tributyl citrate, triethanolamine and triethyl citrate, KolliporTMTPGS, KolliporTMRH40, KolliporTMP188, KolliporTMP407.
  • Additional excipients may be included in the formulation or dose.
  • Non-limiting additional conventional excipients, which may be added, include
  • glidants preservatives, stabilizers, anti-oxidants, silica flow conditioners, antiadherents or glidants, sweetening and other flavouring agents, colouring agents coating materials, preservatives, dyes, thickeners, adjuvants, antimicrobial agents and glidants, controlled release agents for the various formulation types.
  • suitable glidants are selected from the group consisting of colloidal silica, hydrophobic colloidal silica and magnesium trisilicate, such as talcum.
  • Non-limiting examples of suitable controlled release (CR) agents for the production of matrix based CR solid dosage forms are preferably selected from the group consisting of high viscosity water soluble polymerssuch as hydroxypropyl cellulose and
  • hypromellose, and lypophilic matrix forming agents such as glyceryl behenate
  • Non-limiting examples of suitable sweeteners are selected from the group consisting of aspartame, saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia, thaumatin,
  • suitable coating materials are gelatin, wax, shellac or biological degradable polymers, iron oxide
  • Non-limiting examples for suitable preservatives are methyl-, propyl, -or butylparabens, propylene paraben, sorbic acid, chlorobutanol, phenol, thimerosal, potassium sorbate, glycerin, propylene glycol, cysteine and/or methionine.
  • Non-limiting examples for suitable thickeners are synthetic polymers, fatty acids and fatty acid salts and esters and fatty alcohols.
  • Non-limiting other suitable fillers, binders, disintegrants, lubricants and additional excipients which may be used are described in the Handbook of Pharmaceutical Excipients, 5th Edition (2006);The Theory and Practice of industrial Pharmacy, 3rd
  • the formulation product is formed into a suitable dosage form ready for oral administration.
  • Capsules will typically contain the solid composition within a capsule which may be made of gelatin or other conventional encapsulating material.
  • Tablets and powders may be coated. Tablets and powders may be coated with an enteric coating.
  • the enteric coated powder forms may have coatings comprising phthalic acid cellulose acetate, hydroxypropylmethylcellulose phthalate, polyvinylalcohol phthalate,
  • a coated tablet may have a coating on the surface of the tablet or may be a tablet comprising a powder or granules with an enteric coating.
  • Modified release formulations may also be prepared from the solid dispersion according to the invention in order to achieve a more controlled release of the active agent in contact with the body fluids in the gastro intestinal tract, and to provide a substantial constant and effective level of the active agent in the gastric juice.
  • the solid dispersion of the present invention may be embedded for this purpose in a polymer matrix of a biological degradable polymer, a water soluble polymer or a mixture of both, and optionally suitable surfactants. Embedding can mean in this context the incorporation of micro-particles in a matrix of polymers.
  • Modified release formulations can also be obtained through encapsulation of dispersed micro-particles or emulsified micro- droplets via known dispersion or emulsion coating technologies.
  • the pharmaceutical composition facilitates administration of the compound to a mammal, preferably to a human.
  • Idelalisib can be used singly or in combination with one or more therapeutic agents as components of mixtures.
  • Amorphous Idelalisib allows the preparation of pharmaceutical compositions which are bioequivalent to the pharmaceutical composition approved with the US N DA no.
  • X-Ray Powder Diffraction (XRPD) XRPD diffractograms were obtained with an X ' Pert PRO diffractometer (PANalytical, Almelo, The Netherlands) equipped with a theta/theta coupled goniometer in transmission geometry, programmable XYZ stage with well plate holder, Cu K-alpha radiation source (wavelength 0.15418 nm) with a focusing mirror, a 0.5° divergence slit, a 0.02° soller slit collimator and a 0.5° anti-scattering slit on the incident beam side, a 2 mm anti-scattering slit, a 0.02° soller slit collimator, a Ni-filter and a solid state PIXcel detector on the diffracted beam side.
  • the diffractogram was recorded at room temperature (25°C) at a tube voltage of 40 kV, tube current of 40 mA, applying a step size of 0.013° 2-Theta with 40 sec per step in the angular range of 2° to 40° 2-Theta.
  • a typical precision of the 2-Theta values is in the range of ⁇ 0.2° 2-Theta.
  • a diffraction peak that appears for example at 9.4° 2-Theta can appear between 9.2 and 9.6° 2-theta on most X-ray diffractometers under standard conditions.
  • thermogravimetric/differential thermal analyzer TGA/DSC1 with STARe software, Mettler-Toledo LLC, Columbus, USA
  • the sample was then heated under nitrogen (flow rate: 100 cm 3 /min) at a rate of 10°C/min from 30°C to 300°C during which time the change in sample weight was recorded along with any differential thermal events (DTA).
  • the calibration standards were indium and tin.
  • ferf-butanol solvate of idelalisib has a TG/DTA thermogram as illustrated in Fig. 4.
  • Amorphous idelalisib (50 mg) was dissolved at 25°C in 200 ⁇ _ tetrahydrofuran. After a few minutes of stirring, solids began to precipitate. The suspension was stirred at 25°C for 5 days, followed by centrifugation and separation of the precipitate. The solid was then dried, leading to crystalline tetrahydrofuran solvate of idelalisib.
  • the peak list corresponding to the XRPD pattern of crystalline tetrahydrofuran solvate of idelalisib shown in Fig. 5 is given in the following table:
  • tetrahydrofuran solvate of ide alisib had a TG/DTA thermogram as illustrated in Fig. 6.
  • Form I idelalisib (50 mg) was added to /V,/V-dimethylformamide (DMF) at 5°C until undissolved solids remained. The suspension was stirred at 5°C for 5 days, followed by centrifugation and separation of the precipitate. The solid was then dried, leading to crystalline /V,/V-dimethylformamide solvate of idelalisib. 1 H NMR and TG/DTA evaluation showed the solvate to be a 1 : 1 DMF idelalisib solvate.
  • Form I idelalisib (50 mg) was added to 100 ⁇ _ /V,/V-dimethylformamide (DMF) at 5°C. The solution was then added to n-heptane (1 ml.) as anti-solvent at 5°C. Since a solid did not precipitate, the solution was sonicated at 30% intensity using a Cole-Parmer 130W ultrasonic processor, stored at 5°C for 16 h and the solvent was then removed by evaporation, leading to crystalline DMF solvate (1 : 1 ) which had an XRPD and a TG/DTA substantially as shown in Figs. 7 and 8.
  • Pure amorphous idelalisib had a solubility in water at 25°C of about 415 mg/L.
  • Essentially pure amorphous form of idelalisib was prepared according to the following protocol: 25 mg of TH F solvate of idelalisib (prepared according to Example 2) were dissolved in 1 .0 ml. of 1 ,4-dioxane at a temperature of from 40 to 50°C. The solution was sonicated (2 to 5 min in a VWR Ultrasonic Cleaner apparatus) to allow faster solid dissolution.
  • the solution was filtered through a 0.2 ⁇ filter into a round-bottomed flask and rotated within a Dewar flask containing a mixture of liquid nitrogen and acetone, forming a frozen film on the inside of the flask.
  • the flask was lyophilized (plate temperature 20°C, pressure 0.08 mbar) during 18 hours, yielding essentially pure amorphous form of idelalisib.
  • the XRPD pattern of the obtained amorphous idelalisib is shown in Fig. 1 . c) By directly drying tert-BuOH solvate
  • Idelalisib pure (Form I) was suspended in 625ml tert.-BuOH at room temperature. After heating up to 78°C and adding 438 ml of water a solution was formed. The inner temperature decreases to 60°C. The mixture was reheated to 78°C to form a solution. To this solution additional 875 ml of water were slowly added, so that the inner temperature never decreases under 70°C (this inner temperature is necessary to start crystallization during cooling ramp of 5 hours). After addition a slightly turbid mixture was obtained. The mixture was cooled under mixing to 5°C during 5 hours with additional seeding at 52°C. After 1 hour stirring at 5°C, the resulting suspension was filtered via a G3-Nutsch.
  • the wet product was dried under vacuum (30 mbar) at 60°C (at least 40°C) for at least 17 hours to yield 133,3 g of amorphous Idelalisib with a high content of tert.-BuOH (approx. 13%) having good filtering properties.
  • the dried amorphous Idelalisib was suspended in 2600 ml of water and stirred for 4 hours at room temperature.
  • the resulting suspension was filtered via a G3-Nutsch and the wet product was dried under vacuum (30 mbar) at 60°C for at least 17 hours to yield 1 13,8 g amorphous Idelalisib with an lower amount of tert.-BuOH ( approx. ⁇ 1 %).
  • Example 4b 50 mg of pure amorphous idelalisib obtained as disclosed in Example 4b) were added to a KBr pellet die and compressed for 4.5 days at 740 MPa. The resultant solid disc was removed from the press and analysed by XRPD, showing no change in the amorphous phase, as illustrated in Fig. 2.
  • Example 6 Thermal and Humidity Stability of Pure Amorphous Idelalisib a) 98% Relative Humidity 50 mg of pure amorphous idelalisib obtained as disclosed in Example 4b) were exposed to 98% relative humidity at 25°C for 5 days. XRPD analysis provided an XRPD pattern substantially as shown in Fig. 1 , showing no change of the amorphous form. b) 40°C/75% Relative Humidity
  • Example 4b 50 mg of pure amorphous idelalisib obtained as disclosed in Example 4b) were exposed to 75% relative humidity at 40°C for 5 days.
  • XRPD analysis provided an XRPD pattern substantially as shown in Fig. 1 , showing no change of the amorphous form.
  • Example 4b 50 mg of pure amorphous idelalisib obtained as disclosed in Example 4b) were thermally stressed at 120°C and 50% relative humidity for 5 days in a sealed vial.
  • XRPD analysis provided an XRPD pattern substantially as shown in Fig. 1 , showing no change of the amorphous form.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de l'idélalisib amorphe pur et stable, des solvates cristallins d'idélalisib et un procédé pour produire de l'idélalisib amorphe pure et stable à partir des solvates cristallins d'idélalisib.
PCT/EP2015/080537 2014-12-19 2015-12-18 Formes amorphes et cristallines d'idélalisib et procédé pour les produire WO2016097314A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP14199255 2014-12-19
EP14199255.2 2014-12-19
EP14199739 2014-12-22
EP14199739.5 2014-12-22
EP15151854.5A EP3048104A1 (fr) 2015-01-20 2015-01-20 Idelalisib amorphe et des forms cristalline et leur procédé de fabrication
EP15151854.5 2015-01-20

Publications (1)

Publication Number Publication Date
WO2016097314A1 true WO2016097314A1 (fr) 2016-06-23

Family

ID=55066592

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/080537 WO2016097314A1 (fr) 2014-12-19 2015-12-18 Formes amorphes et cristallines d'idélalisib et procédé pour les produire

Country Status (1)

Country Link
WO (1) WO2016097314A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106632337A (zh) * 2016-10-18 2017-05-10 湖北生物医药产业技术研究院有限公司 艾代拉里斯的晶型、药物组合物、制备方法和用途
EP3272348A1 (fr) * 2016-07-21 2018-01-24 LEK Pharmaceuticals d.d. Composition pharmaceutique comportant de l'idelalisib
US10370376B2 (en) * 2015-04-15 2019-08-06 Alnova Pharmaceuticals, Ltd. Amorphous substance of Idelalisib and preparation method therefor
WO2019178596A1 (fr) 2018-03-16 2019-09-19 Johnson Matthey Public Limited Company Formes à l'état solide solvatées de pyridine ou de n,n-diméthylacétamide d'idélalisib solvaté, leur utilisation et leur préparation
US10463669B2 (en) * 2016-02-15 2019-11-05 Seoul National University R&Db Foundation Composition for treating or preventing liver cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113554A2 (fr) * 2004-05-13 2005-12-01 Icos Corporation Méthode de préparation du 3-phényle-2-[9h-purine-6-ylamino)-méthyle]-3h-quinazoline-4-un et composés substitués et associés
WO2013134288A1 (fr) * 2012-03-05 2013-09-12 Gilead Calistoga Llc Formes polymorphes de l'acide -2-(1-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one
CN104130261A (zh) * 2014-08-04 2014-11-05 山东康美乐医药科技有限公司 艾德利布的合成方法
WO2015092810A2 (fr) * 2013-11-20 2015-06-25 Cadila Healthcare Limited Forme amorphe d'idélalisib
WO2015095605A1 (fr) * 2013-12-20 2015-06-25 Gilead Calistoga Llc Formes polymorphes d'un sel chlorhydrate de la (s)-2-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113554A2 (fr) * 2004-05-13 2005-12-01 Icos Corporation Méthode de préparation du 3-phényle-2-[9h-purine-6-ylamino)-méthyle]-3h-quinazoline-4-un et composés substitués et associés
WO2013134288A1 (fr) * 2012-03-05 2013-09-12 Gilead Calistoga Llc Formes polymorphes de l'acide -2-(1-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one
WO2015092810A2 (fr) * 2013-11-20 2015-06-25 Cadila Healthcare Limited Forme amorphe d'idélalisib
WO2015095605A1 (fr) * 2013-12-20 2015-06-25 Gilead Calistoga Llc Formes polymorphes d'un sel chlorhydrate de la (s)-2-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one
CN104130261A (zh) * 2014-08-04 2014-11-05 山东康美乐医药科技有限公司 艾德利布的合成方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "A Review of Polymorphism and the Amorphous State in the Formulation Strategy of Medicines | Articles | PharmaXChange.info", 3 September 2011 (2011-09-03), XP055130130, Retrieved from the Internet <URL:http://pharmaxchange.info/press/2011/09/a-review-of-polymorphism-and-the-amorphous-state-in-the-formulation-strategy-of-medicines/> [retrieved on 20140718] *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10370376B2 (en) * 2015-04-15 2019-08-06 Alnova Pharmaceuticals, Ltd. Amorphous substance of Idelalisib and preparation method therefor
US10463669B2 (en) * 2016-02-15 2019-11-05 Seoul National University R&Db Foundation Composition for treating or preventing liver cancer
EP3272348A1 (fr) * 2016-07-21 2018-01-24 LEK Pharmaceuticals d.d. Composition pharmaceutique comportant de l'idelalisib
CN106632337A (zh) * 2016-10-18 2017-05-10 湖北生物医药产业技术研究院有限公司 艾代拉里斯的晶型、药物组合物、制备方法和用途
CN106632337B (zh) * 2016-10-18 2018-11-20 湖北生物医药产业技术研究院有限公司 艾代拉里斯的晶型、药物组合物、制备方法和用途
WO2019178596A1 (fr) 2018-03-16 2019-09-19 Johnson Matthey Public Limited Company Formes à l'état solide solvatées de pyridine ou de n,n-diméthylacétamide d'idélalisib solvaté, leur utilisation et leur préparation
US11358966B2 (en) 2018-03-16 2022-06-14 Johnson Matthey Public Limited Company Pyridine or N,N-dimethyl acetamide solvated solid state forms of solvated idelalisib, their use and preparation

Similar Documents

Publication Publication Date Title
KR101737250B1 (ko) 개선된 생체이용률을 갖는 약학 조성물
WO2016097314A1 (fr) Formes amorphes et cristallines d&#39;idélalisib et procédé pour les produire
AU2014283231B2 (en) Amorphous Letermovir and solid pharmaceutical formulations thereof for oral administration
WO2011098582A2 (fr) Nouvelles formes de chlorhydrate d&#39;ivabradine
CN111164085B (zh) 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途
JP2005533755A (ja) ランソプラゾール多形及びその調製方法
WO2014076712A2 (fr) Dispersion solide de chlorhydrate de lurasidone
EP2714676B1 (fr) Procédé pour la préparation de la forme polymorphe i de l&#39;étoricoxib
WO2016097030A1 (fr) Composition pharmaceutique comprenant du lenalidomine amorphe
JP2020500912A (ja) ブロモドメインタンパク質阻害薬の結晶形及びその製造方法並びに用途
EA017553B1 (ru) Гидробромид ивабрадина
EA035390B1 (ru) Совместный осадок тадалафила с фармацевтически приемлемыми эксципиентами, содержащая его фармацевтическая композиция и способ их получения
AU2002338726B2 (en) Pseudopolymorphic forms of carvedilol
CN110312705B (zh) Gft-505的晶型及其制备方法和用途
US20200323838A1 (en) Lenalidomide immediate release formulations
AU2017254950B2 (en) Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein
EP3048104A1 (fr) Idelalisib amorphe et des forms cristalline et leur procédé de fabrication
KR102276281B1 (ko) 의약으로 사용하기 위한 펄린돌 광학이성질체의 약학적으로 허용가능한 염
CA3086611C (fr) Forme cristalline de ditosylate de valbenazine, procedes de preparation et utilisation
US20190233400A1 (en) Crystalline Form of Olaparib
JP3547009B1 (ja) ５−［（１ｚ，２ｅ）−２−メチル−３−フェニル−２−プロペニリデン］−４−オキソ−２−チオキソ−３−チアゾリジン酢酸の新規結晶、その製造方法およびその結晶を有効成分とする医薬
EP3601278B1 (fr) Forme cristalline de masitinibe
CA2955397C (fr) Nouvelle forme cristalline de methanesulfonate de 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide et co mposition pharmaceutique le contenant
US20240000769A1 (en) Amorphous solid dispersions
WO2021006267A1 (fr) Sel de dérivé de pyrazole et préparation de dérivé de pyrazole

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15817810

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15817810

Country of ref document: EP

Kind code of ref document: A1